

AXUMIN®
Fluciclovine F 18 Injection

Axumin Scheduling Sheet

If you would like to refer a patient for an Axumin PET/CT scan, please complete this form and fax it to an Axumin imaging site. To locate an Axumin imaging site, visit www.axumin.com/imaging-center-locator.

PATIENT INFORMATION

Patient name	Date of birth	Phone

Primary insurance	Subscriber ID	Prior authorization #

Secondary insurance	Subscriber ID	Prior authorization #

Secondary insurance	Subscriber ID	Prior authorization #

CLINICAL SIGNS/SYMPTOMS

Diagnosis	Clinical question	ICD-10 code(s)

SPECIFIC REASON FOR AXUMIN PET STUDY

☐ Suspicion of recurrent disease after previously treated prostate cancer

Suspected recurrence based on:	Elevated PSA levels:

Special instructions:

PRIOR STUDIES/TREATMENT

Radical prostatectomy
☐ Yes ☐ No

Radiation therapy to prostate
☐ Yes ☐ No

Other treatments (describe)

Physician	Date
Physician	Date
Physician	Date

PREVIOUS SCANS

☐ CT ☐ MR ☐ Bone scan

Location	Date

I verify that the above information is complete and accurate to the best of my knowledge and that I have prescribed Axumin based on my independent professional judgment of medical necessity.

Physician or nurse practitioner signature	Date

Please see Axumin Important Safety Information on back.

Axumin Scheduling Sheet

AXUMIN®
Fluciclovine F 18 Injection

PATIENT PREPARATION AND PRECAUTIONS

Preparing for an Axumin scan

- Patient should avoid any significant exercise for at least 1 day prior to PET/CT imaging
- Patient should fast for at least 4 hours prior to administration (other than sips of water for taking medications)
- Patient should empty their bladder 30 to 60 minutes prior to administration. Patient should avoid further urination until after the scan is over
- The total scan time is between 20 and 30 minutes

INDICATION

Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
- Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Axumin Prescribing Information, also available at www.axumin.com.

BLUE EARTH DIAGNOSTICS
A Bracco Company

BEDPRC21-0079D 9/21